Evidence map›Paper›PMID 32801647›Full record

ArticleDrug design, development and therapy2020

Nano-Graphene Oxide-supported APTES-Spermine, as Gene Delivery System, for Transfection of pEGFP-p53 into Breast Cancer Cell Lines.

Vida Mirzaie, Mehdi Ansari, Seyed Noureddin Nematollahi-Mahani, Mahshid Moballegh Nasery, Behzad Karimi, Touba Eslaminejad, Yaghoub Pourshojaei

Open access · goldAbstract read
In one paragraph

Article in Drug design, development and therapy, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
1.2field-weighted citation impact, top 23% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 23 citations in OpenAlex.

  1. Review
  2. Article
  3. Review
  4. Article
  5. Review
  6. Review
  7. Review
  8. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 2 institutions in 1 country.

Vida MirzaieDepartment of Anatomy, Afzalipour School of Medicine, Kerman University of Medical Sciences, Kerman, Iran.ORCID 0000-0001-7052-2013
Mehdi AnsariDepartment of Drug and Food Control, Faculty of Pharmacy, Kerman University of Medical Sciences, Kerman, Iran.ORCID 0000-0003-4637-553X
Seyed Noureddin Nematollahi-MahaniDepartment of Anatomy, Afzalipour School of Medicine, Kerman University of Medical Sciences, Kerman, Iran.
Mahshid Moballegh NaseryPharmaceutics Research Centre, Institute of Neuropharmacology, Kerman University of Medical Sciences, Kerman, Iran.ORCID 0000-0001-7662-9161
Behzad KarimiSurface Coating and Corrosion Department, Institute for Color Science and Technology, Tehran, Iran.
Touba EslaminejadPharmaceutics Research Centre, Institute of Neuropharmacology, Kerman University of Medical Sciences, Kerman, Iran.
Yaghoub PourshojaeiDepartment of Medicinal Chemistry, Faculty of Pharmacy and Pharmaceutics Research Center, Kerman University of Medical Sciences, Kerman, Iran.
Kerman University of Medical Sciences · IRInstitute for Color Science and Technology · IR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposeGenetic diseases can be the result of genetic dysfunctions that happen due to some inhibitory and/or environmental risk factors, which are mostly called mutations. One of the most promising treatments for these diseases is correcting the faulty gene. Gene delivery systems are an important issue in improving the gene therapy efficiency. Therefore, the main purpose of this study was modifying graphene oxide nanoparticles by spermine in order to optimize the gene delivery system.

methodsGraphene oxide/APTES was modified by spermine (GOAS) and characterized by FT-IR, DLS, SEM and AFM techniques. Then pEGFP-p53 was loaded on GOAS, transfected into cells and evaluated by fluorescent microscopy and gene expression techniques.

resultsFT-IR data approved the GOAS sheet formation. Ninety percent of the particles were less than 56 nm based on DLS analysis. SEM analysis indicated that the sheets were dispersed with no aggregation. AFM results confirmed the dispersed structures with thickness of 1.25±0.87 nm. STA analysis showed that GOAS started to decompose from 400°C and was very unstable during the heating process. The first weight loss up to 200°C was due to the evaporation of absorbed water, the second one observed in the range of 200-550°C was assigned to the decomposition of labile oxygen- and nitrogen-containing functional groups, and the third one above 550°C was attributed to the removal of oxygen functionalities. In vitro release of DNA demonstrated the efficient activity of the new synthesized system. Ninety percent of the cells were transfected and showed the GFP under fluorescence microscopy, and

conclusionIt could be concluded that the new synthesized structure could transfer a high amount of the therapeutic agent into cells with best activity.

Indexed as

Genetic TherapyGene Transfer TechniquesBreast NeoplasmsFemaleGraphiteGreen Fluorescent ProteinsHumansMicroscopy, FluorescenceNanoparticlesPropylaminesSilanesSpectroscopy, Fourier Transform InfraredSpermineTransfectionTumor Cells, CulturedTumor Suppressor Protein p53amino-propyl-triethoxysilanegraphene oxideGraphiteGreen Fluorescent ProteinsPropylaminesSilanesSpermineTumor Suppressor Protein p53conjugated polymerDNA carriergene transferin vitroMCF-7 cellsnanomedicine

Identifiers

PMID32801647
PMCPMC7398748
OpenAlexW3045646506

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.